BioCentury | Oct 30, 2020
Product Development

José Baselga on how new modalities and biomarkers are shaping AZ’s oncology strategy

...research.Baselga also co-founded the synthetic lethality-focused biotech Tango...
BioCentury | Aug 18, 2020
Product Development

Gilead, Tango expand cancer partnership; plus Roche approval, Novavax COVID-19 efficacy study and G1, Myovant and PTC applications under review

...in Tango, expands 2018 dealGilead Sciences Inc. (NASDAQ:GILD) million has expanded its 2018 deal with Tango...
...immuno-oncology targets in exchange for $125 million up front and a $20 million equity investment. Tango...
...double-digit tiered royalties. Tango may co-promote and co-develop up to five programs in the U.S. (see “Tango...
BioCentury | Apr 18, 2020
Product Development

Investors are still waiting for the other shoe to drop on a slowdown in deal flow

...are consistent with the previous four quarters. Source: BioCentury's BCIQ database Lauren Martz, Senior Editor Sofinnova Partners Novartis AG Tango...
BioCentury | Apr 9, 2020
Finance

As Tango moves toward clinic with $60M series B, another partnership could precede IPO

...Although synthetic lethality company Tango’s $60 million series B round includes crossover investors who might normally...
...advanced programs are generally among Tango’s oldest ones; others may create opportunities for business development. Tango...
...exceeds $1.7 billion (see “Tango, Gilead Partner” ). The deal’s upfront payment, which nearly matched Tango’s...
BioCentury | Mar 17, 2020
Product Development

March 16 Quick Takes: FDA raises efficacy questions for DBV allergy therapy; plus Novo, Provention, UCB, Pfizer-EMD Serono, Zai, AcelRx-Tetraphase, Medivir-Tan

...for the antibiotic Xerava eravacycline. Medivir enters preclinical cancer deal with Tango Synthetic lethality company Tango...
...for undisclosed upfront and development and commercial milestone payments as well as low single-digit royalties. Tango...
...TP-434) teplizumab (MGA031, PRV-031) Viaskin Peanut (DBV-712) Novo Nordisk A/S UCB S.A. Merz GmbH & Co. KGaA Pfizer Inc. Zai Lab Ltd. Medivir AB Tango...
BioCentury | Feb 28, 2020
Deals

Biogen expands its modality toolkit in Alzheimer’s and Parkinson’s with Sangamo deal

...supranuclear palsy (PSP). The company is continuing to evaluate the mAb in the Phase II TANGO...
BioCentury | Dec 13, 2019
Clinical News

Phase II miss dims outlook for Biogen’s anti-tau mAb from Bristol deal

...it would have been “in a position to file for regulatory approval.” The Phase II TANGO...
BioCentury | Sep 3, 2019
Company News

Management tracks: Tempus brings on former FDA chief of staff; plus Bayer, Genfit, Accent and more

...company Accent Therapeutics Inc. (Lexington, Mass.) hired Shakti Narayan as CEO. He was CBO of Tango...
BioCentury | Jul 10, 2019
Clinical News

July 10 Clinical Quick Takes: Darzalex quad combo raises MM complete response, plus Geneos and ViiV

...primary endpoint of non-inferiority vs. triple combinations containing tenofovir alafenamide fumarate in the Phase III TANGO...
BioCentury | Jan 11, 2019
Emerging Company Profile

Artios: Probing DNA Damage

...developing a POLQ inhibitor and expects to enter the clinic by 2021. Both Repare and Tango...
...Tango Therapeutics Inc., Cambridge, Mass. Elizabeth S. Eaton, Staff Writer Artios Pharma Ltd. Cancer Research UK Masaryk University Repare Therapeutics Inc. Tango...
Items per page:
1 - 10 of 62